DPYD Polyclonal Antibody

Dihydropyrimidine dehydrogenase [NADP(+)] encoded by DPYD is a pyrimidine catabolic enzyme and the initial and rate-limiting factor in the pathway of uracil and thymidine catabolism. Mutations in this gene result in dihydropyrimidine dehydrogenase deficiency, an error in pyrimidine metabolism associated with thymine-uraciluria and an increased risk of toxicity in cancer patients receiving 5-fluorouracil chemotherapy. Two transcript variants encoding different isoforms have been found for this gene.

The DPYD Polyclonal Antibody is a highly specific and sensitive tool designed for the detection and quantification of DPYD protein expression in various biological samples. This antibody is produced using state-of-the-art techniques, ensuring high affinity and specificity towards DPYD.

DPYD, also known as dihydropyrimidine dehydrogenase, is a key enzyme involved in the metabolism of fluoropyrimidine-based chemotherapeutic agents. It plays a crucial role in the inactivation of these drugs, thereby affecting their efficacy and toxicity.

The DPYD Polyclonal Antibody is validated for use in various applications, including Western blotting, immunohistochemistry, and immunofluorescence. It exhibits excellent performance in detecting DPYD protein expression in both normal and cancerous tissues.

With its superior sensitivity and specificity, this antibody enables researchers and clinicians to accurately assess DPYD expression levels, facilitating personalized medicine approaches and optimizing treatment strategies for patients undergoing fluoropyrimidine-based chemotherapy.

The DPYD Polyclonal Antibody is supplied as a liquid formulation, ready to use for immediate experimentation. It is available in different sizes to meet the diverse needs of researchers and laboratories.

In summary, the DPYD Polyclonal Antibody is a reliable and efficient tool for the detection and quantification of DPYD protein expression. Its high specificity and sensitivity make it an invaluable asset in cancer research and clinical practice, aiding in the development of personalized treatment plans for patients.